Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
18 October 2019. Related: Conference reports, Antiretrovirals.
Conference reports
Switching from TDF to TAF linked to higher BMI and cardio risk
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Possible higher diabetes risk with raltegravir or PIs than NNRTIs
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives
18 October 2019. Related: Conference reports, PK and drug interactions.
Over half of mostly black US HIV group has NAFLD – and many have NASH
18 October 2019. Related: Conference reports, Lipodystrophy and metabolic complications.
People taking more medications and women have higher fall risk in older HIV group
18 October 2019. Related: Conference reports, Coinfections and complications, Ageing and life expectancy.
No link between raltegravir and adverse birth outcomes in analysis in 2550 women
18 October 2019. Related: Conference reports, Pregnancy.
PrEP linked to lower HIV incidence in US, independent of TasP
18 October 2019. Related: Conference reports, HIV prevention and transmission.
10th IAS Conference on HIV Science (IAS 2019): final reports
30 September 2019. Related: Conference reports.
Low rates of pregnancy with three methods of contraception in the ECHO trial
30 September 2019. Related: Conference reports, Pregnancy.
Other pregnancy studies IAS 2019
17 September 2019. Related: Conference reports, Pregnancy.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
23 August 2019. Related: Conference reports.
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
23 August 2019. Related: Conference reports, Treatment strategies.
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
23 August 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.
Dolutegravir for younger children: results from the ODYSSEY trial
23 August 2019. Related: Conference reports, Paediatric care.
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
23 August 2019. Related: Conference reports, HIV prevention and transmission.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
24 July 2019. Related: Conference reports.
Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals
24 July 2019. Related: Conference reports, Pregnancy.
WHO recommends dolutegravir-based ART regimens for all
24 July 2019. Related: Conference reports, Guidelines.
High rates of viral suppression with low dose efavirenz in pregnant Zambian women
24 July 2019. Related: Conference reports, Pregnancy.
First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results
24 July 2019. Related: Conference reports, Antiretrovirals.
Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy
24 July 2019. Related: Conference reports, Antiretrovirals.
Fostemsavir: 96-week follow-up in people with multi-drug resistance
24 July 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96
24 July 2019. Related: Conference reports, Antiretrovirals.
Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year
24 July 2019. Related: Conference reports, HIV prevention and transmission.
Upcoming 10th IAS Conference on HIV Science (IAS 2019)
17 July 2019. Related: Conference reports.
IAS 2019: late breaker highlights to look for
17 July 2019. Related: Conference reports, Antiretrovirals.
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs
19 June 2019. Related: Conference reports.
Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine
19 June 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Drug-drug interactions between efavirenz and levonorgestrel influenced by genetic variants
19 June 2019. Related: Conference reports, Women's health, PK and drug interactions.
Infant dolutegravir exposure through placental and breastmilk transfer
19 June 2019. Related: Conference reports, Pregnancy, PK and drug interactions.
Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s
19 June 2019. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
13th INTEREST workshop 14–17 May 2019, Accra, Ghana
20 May 2019. Related: Conference reports.
No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study
20 May 2019. Related: Conference reports, Pregnancy.
25th Annual BHIVA Conference (BHIVA 2019)
20 May 2019. Related: Conference reports.
Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study
20 May 2019. Related: Conference reports, HIV prevention and transmission.
Management of testosterone deficiency in HIV positive people
20 May 2019. Related: Conference reports, Coinfections and complications.
Importance of including menopause and bone health in management of HIV positive women
20 May 2019. Related: Conference reports, Women's health.
Type 2 diabetes is often undermanaged in HIV positive people
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
Adopting new US blood pressure targets for HIV positive people could reduce cardiovascular-related deaths
20 May 2019. Related: Conference reports, Side effects, Coinfections and complications.
Selected webcasts from BHIVA 2019
20 May 2019. Related: Conference reports, On the web.
Conference on Retroviruses and Opportunistic Infections (CROI 2019) 4–7 March, 2019
20 May 2019. Related: Conference reports.
INSTI and weight gain: reports from CROI 2019
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
B/F/TAF suitable for children from six years of age
20 May 2019. Related: Conference reports, Paediatric care.
25th Annual BHIVA Conference (BHIVA 2019)
30 April 2019. Related: Conference reports.
BHIVA preconference: U=U and HIV and immigration detention
30 April 2019. Related: Conference reports, Treatment access, HIV prevention and transmission.
Conference on Retroviruses and Opportunistic Infections (CROI 2019): third reports
30 April 2019. Related: Conference reports.
bNAb research at CROI 2019: vaccine, prevention, treatment and cure…
30 April 2019. Related: Conference reports, Treatment strategies, HIV prevention and transmission, Cure-related research.
Paediatric dolutegravir update
30 April 2019. Related: Conference reports, Paediatric care.
Other cure related studies at CROI 2019
30 April 2019. Related: Conference reports, Cure-related research.
Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports
28 March 2019. Related: Conference reports.
Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10
28 March 2019. Related: Conference reports, Antiretrovirals.
Capsid inhibitor GS-6207 shows potential for 3-monthly injections
28 March 2019. Related: Conference reports, Antiretrovirals.
First phase 1 results from bNAb PGT121 in HIV positive people
28 March 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Same-day ART is effective in San Francisco Rapid-ART clinic
28 March 2019. Related: Conference reports, Antiretrovirals, Treatment strategies.
Integrase inhibitors and neural tube defects: more data still needed
28 March 2019. Related: Conference reports, Pregnancy.
Double-dose levonorgestrel implant does not overcome interaction with efavirenz
28 March 2019. Related: Conference reports, Women's health, PK and drug interactions.
Efavirenz and rifampicin together reduce levels of injectable contraception
28 March 2019. Related: Conference reports, Women's health, PK and drug interactions.
Bedaquiline and delamanid safe when given together to treat drug resistant TB
28 March 2019. Related: Conference reports, TB coinfection.
Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes
28 March 2019. Related: Conference reports, TB coinfection.
Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports
12 March 2019. Related: Conference reports.